Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Endometrial02: T-DXd vs Chemotherapy as Adjuvant Treatment for HER2-Expressing Endometrial Cancer
NCT07022483Phase 3Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Sep 2025
- Primary completion
- Feb 2030
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, open-label trial in endometrial cancer (EC) comparing Arm A: T-DXd with Arm B: Standard of Care Chemotherapy (2 arms). Primary endpoint: Disease-Free Survival. Started Sep 2025; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT07022483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07022483.